Get the Stockscreener App
45.60
0.11%
0.05
After Hours:
45.60
Quidelortho Corporation stock is traded at $45.60, with a volume of 472.04K.
It is up +0.11% in the last 24 hours and up +7.93% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
See More
Previous Close:
$45.55
Open:
$45.52
24h Volume:
472.04K
Relative Volume:
0.43
Market Cap:
$3.07B
Revenue:
$2.83B
Net Income/Loss:
$-1.86B
P/E Ratio:
240.00
EPS:
0.19
Net Cash Flow:
$-170.10M
1W Performance:
+1.92%
1M Performance:
+7.93%
6M Performance:
-4.88%
1Y Performance:
-37.57%
1-Day Range:
$44.80
$45.90
1-Week Range:
$42.92
$45.98
52-Week Range:
$29.73
$75.86
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
QuidelOrtho's SWOT analysis: stock outlook amid cost cuts, product delays - Investing.com
Renaissance Technologies LLC Has $3.47 Million Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
Hsbc Holdings PLC Increases Stake in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
Maverick Capital Ltd. Boosts Stake in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
105,378 Shares in QuidelOrtho Co. (NASDAQ:QDEL) Purchased by Dark Forest Capital Management LP - MarketBeat
QuidelOrtho Corp (QDEL) Stock Price Down 4.21% on Sep 25 - GuruFocus.com
Oracle Investment Management Inc. Has $3.93 Million Position in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
You are viewing the "QuidelOrtho" Archives - WOUB
Integral Health Asset Management LLC Invests $4.98 Million in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
American Century Companies Inc. Purchases 18,799 Shares of QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho Co. (NASDAQ:QDEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Rubric Capital Management LP Acquires 1,245,590 Shares of QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
Edgestream Partners L.P. Has $1.94 Million Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
UBS Upgrades QuidelOrtho (QDEL) - MSN
Cracking The Code: Understanding Analyst Reviews For QuidelOrtho - Benzinga
QuidelOrtho Receives FDA Approval for STD Assay - San Diego Business Journal
Carlyle Group Inc. Has $382.72 Million Stake in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
WINTON GROUP Ltd Acquires Shares of 140,546 QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho (NASDAQ:QDEL) Seems To Be Using A Lot Of Debt - Simply Wall St
LSV Asset Management Lowers Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer - sharewise
Monaco Asset Management SAM Takes Position in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer - Business Wire
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer - Silicon UK
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer - StockTitan
Private Management Group Inc. Has $20.29 Million Position in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
TD Asset Management Inc Buys 26,364 Shares of QuidelOrtho Co. (NASDAQ:QDEL) - Defense World
Zurcher Kantonalbank Zurich Cantonalbank Buys 667 Shares of QuidelOrtho Co. (NASDAQ:QDEL) - Defense World
Bank of New York Mellon Corp Trims Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho rises as Craig-Hallum upgrades on earnings power - MSN
Why QuidelOrtho Stock Blasted 10% Higher Today - sharewise
Why QuidelOrtho Stock Blasted 10% Higher Today - MSN
QuidelOrtho (QDEL) Stock Surges on Analyst Upgrade - GuruFocus.com
Why QuidelOrtho Stock Blasted 10% Higher Today - The Motley Fool
Quidel shares lifted to buy, target raised on earnings potential - Investing.com
QuidelOrtho rises as Craig-Hallum upgrades on earnings power (NASDAQ:QDEL) - Seeking Alpha
Craig-Hallum ups QuidelOrtho to Buy on untapped earnings power - TipRanks
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - MSN
QuidelOrtho receives FDA 510(k) clearance for its VITROS syphilis assay - SelectScience
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - Zacks Investment Research
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - Yahoo Finance
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue? - MSN
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod - MSN
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod - Yahoo Finance
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod - Zacks Investment Research
QuidelOrtho gains FDA approval for syphilis test By Investing.com - Investing.com Canada
QuidelOrtho gains FDA approval for syphilis test - Investing.com
VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S. - sharewise
QuidelOrtho gains FDA approval for syphilis test By Investing.com - Investing.com UK
VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S. - Business Wire
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):